Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 2/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7827157 | 0.88 | AKR1B1 (0.67) | CXCL8AKR1B1TDP1LMNAPTGS2 | |
| SCHEMBL9890644 | 0.87 | CXCL8 (0.53) | CXCL8AKR1B1TDP1LMNARAB9A | |
| SCHEMBL9890652 | 0.84 | CXCL8 (0.50) | CXCL8AKR1B1PTGS2 | |
| SCHEMBL9890682 | 0.84 | CXCL8 (0.50) | CXCL8AKR1B1PTGS2PTGDR2 | |
| SCHEMBL9890684 | 0.84 | CXCL8 (0.50) | CXCL8AKR1B1PTGS2PTGDR2 | |
| SCHEMBL9890654 | 0.84 | CXCL8 (0.50) | CXCL8AKR1B1 | |
| SCHEMBL9890678 | 0.84 | CXCL8 (0.49) | CXCL8AKR1B1LMNARAB9APTGS2 | |
| SCHEMBL29533621 | 0.84 | CXCL8 (0.65) | CXCL8AKR1B1TDP1LMNARAB9A | |
| SCHEMBL8645 | 0.84 | CXCL8 (0.65) | CXCL8AKR1B1TDP1LMNARAB9A | |
| SCHEMBL2391854 | 0.83 | ALDH1A1 (0.45) | CXCL8LMNARAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050438-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | ATHENEX, INC. | 2024-02-15 | — | — | US | disclosed |
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2022-04-21 | — | — | US | disclosed |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2021-08-19 | — | — | US | disclosed |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | OAKTREE FUND ADMINISTRATION, LLC | 2017-07-13 | — | — | US | disclosed |
| US-9655903-B2 | Compositions and methods of treating cell proliferation disorders | ATHENEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9580387-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150182532-A1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2015-07-02 | — | — | US | disclosed |
| US-8980890-B2 | Compositions and methods of treating cell proliferation disorders | KINEX PHARMACEUTICALS, LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140213587-A1 | Biaryl Compositions and Methods for Modulating a Kinase Cascade | KINEX PHARMACEUTICALS, LLC (US) | 2014-07-31 | — | — | US | disclosed |
| US-20050026849-A1 | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases | TRINITY LABORATORIES, INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2004087121-A2 | WATER SOLUBLE FORMULATIONS OF DIGITALIS GLYCOSIDES FOR TREATING CELL-PROLIFERATIVE AND OTHER DISEASES | AZAYA THERAPEUTICS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040014695-A1 | Mixture of cytolysis drug and cyclodextrin; side effect reduction; reducing ulcers | SUPERGEN, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6583125-B2 | Antiulceration effective amount of a substituted cyclodextrin compound and a cytotoxic drug, especially an anticancer drug; side effect reduction | SUPERGEN, INC. | 2003-06-24 | — | — | US | disclosed |
| US-20020058634-A1 | Formulation of nitrogen mustard | SUPERGEN, INC. | 2002-05-16 | — | — | US | disclosed |
| US-6284747-B1 | MIXTURE OF CYCLODEXTRIN AND CYTOTOXIC AGENT | SUPERGEN, INC. | 2001-09-04 | — | — | US | disclosed |
| US-6218374-B1 | ADMINISTERING TO HOST, PREPARATION COMPRISING CYTOTOXIC COMPOUND THAT HAS POTENTIAL FOR CAUSING ULCERATION AND SUBSTITUTED CYCLODEXTRIN COMPOUND FOR REDUCING ULCERATION AND IRRITATION | SUPERGEN, INC. | 2001-04-17 | — | — | US | disclosed |
| US-6048845-A | ANTIULCER AGENT; MIXTURE OF CYCLODEXTRI AD CYTOTOXIC DRUG | SUPERGEN, INC. (US) | 2000-04-11 | — | — | US | disclosed |
| US-5824668-A | Formulation for administration of steroid compounds | SUPERGEN, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| US-5804568-A | PARENTERAL ADMINISTRATION OF CYTOTOXIC DRUG MIXED WITH ANTIULCERATIVE AMOUNT OF SUBSTITUTED CYCLODEXTRIN; SIDE EFFECT REDUCTION | SUPERGEN, INC. (US) | 1998-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K2, MAP3K6, MAP3K8 | CXCL8 3327/4885AKR1B1 2103/4885TDP1 2298/4885 |
| US-20140213587-A1 | Biaryl Compositions and Methods for Modulating a Kinase Cascade | MAP3K3, MAP3K2, MAP3K20 | CXCL8 3492/4885AKR1B1 2759/4885TDP1 1443/4885 |
| US-20240050438-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | CXCL8 3492/4885AKR1B1 2759/4885TDP1 1443/4885 |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | CXCL8 3492/4885AKR1B1 2759/4885TDP1 1443/4885 |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K2, MAP3K3, MAP3K6 | CXCL8 3885/4885AKR1B1 1684/4885TDP1 2252/4885 |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | CXCL8 3492/4885AKR1B1 2759/4885TDP1 1443/4885 |
| US-20150182532-A1 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | MKI67, CCNC, CCNA1 | CXCL8 1944/4885AKR1B1 1372/4885TDP1 2054/4885 |
| US-20050026849-A1 | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases | NISCH, CANX, DSC1 | CXCL8 1746/4885AKR1B1 3392/4885TDP1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.